Broadcast Date: June 17, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Drug developers have been identifying novel disease targets and biological mechanisms to look for more potent and effective therapeutics. Consequently, biologic pipelines are evolving from standard antibody formats to next-generation biologics such as bispecific antibodies (bsAbs). Such molecules are often difficult to express, and developing productive processes are an industry challenge. Now more than ever before, there is a real need for a robust and scalable expression platform that can keep pace with these requirements.

In this GEN webinar, Dr. Jizu Yi will share his experiences on key upstream challenges for the expression of YBODY® and CHECKBODY® based bsAbs. Dr. Yi will discuss how his lab successfully developed strategies using the GS Xceed® Expression System to construct cell lines with high productivity and product quality in a short time span—concluding with how his organization managed to control the level of impurities during manufacturing.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelists.

Jizu Yi, PhD
Jizu Yi, PhD
Senior Vice President
YZY Biopharma
Devarshi Kapadia
Devarshi Kapadia
Product Manager, Expression Systems
Lonza

Lonza Biologics logo

The post Bispecific Antibody Development: Upstream Challenges and Strategies appeared first on GEN – Genetic Engineering and Biotechnology News.

Source